These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19417146)

  • 1. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.
    Yan T; Deng S; Metzger A; Gödtel-Armbrust U; Porter AC; Wojnowski L
    Mol Cancer Ther; 2009 May; 8(5):1075-85. PubMed ID: 19417146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
    Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
    BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
    Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
    Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
    Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
    Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
    Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
    Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
    Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
    Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
    Hasinoff BB; Patel D; Wu X
    Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
    Hasinoff BB; Yalowich JC; Ling Y; Buss JL
    Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.
    Grauslund M; Thougaard AV; Füchtbauer A; Hofland KF; Hjorth PH; Jensen PB; Sehested M; Füchtbauer EM; Jensen LH
    Mol Pharmacol; 2007 Oct; 72(4):1003-14. PubMed ID: 17622580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
    Hasinoff BB; Herman EH
    Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
    Hasinoff BB; Abram ME; Barnabé N; Khélifa T; Allan WP; Yalowich JC
    Mol Pharmacol; 2001 Mar; 59(3):453-61. PubMed ID: 11179439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.
    Heestand GM; Schwaederle M; Gatalica Z; Arguello D; Kurzrock R
    Eur J Cancer; 2017 Sep; 83():80-87. PubMed ID: 28728050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
    Arivazhagan A; Kumar DM; Sagar V; Patric IR; Sridevi S; Thota B; Srividya MR; Prasanna K; Thennarasu K; Mondal N; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
    J Neurooncol; 2012 Apr; 107(2):289-97. PubMed ID: 22102081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
    Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
    Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
    Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
    PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
    Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
    Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.